-
Oct 2015
Inhibition of hyaluronan synthesis restores immune tolerance during autoimmune insulitis.
J Clin InvestNagy N, Kaber G, Johnson PY, Gebe JA, Preisinger A, Falk BA, Sunkari VG, Gooden MD, Vernon RB, Bogdani M, Kuipers HF, Day AJ, Campbell DJ, Wight TN, Bollyky PL -
Aug 2015
Hyaluronan: A Mediator of Islet Dysfunction and Destruction in Diabetes?
J Histochem CytochemHull RL, Bogdani M, Nagy N, Johnson PY, Wight TN -
Jan 2015
The detection of glycosaminoglycans in pancreatic islets and lymphoid tissues.
Methods Mol BiolBogdani M, Simeonovic C, Nagy N, Johnson PY, Chan CK, Wight TN -
Nov 2014
Assessment of CD4+ T cell responses to glutamic acid decarboxylase 65 using DQ8 tetramers reveals a pathogenic role of GAD65 121-140 and GAD65 250-266 in T1D development.
PLoS OneChow IT, Yang J, Gates TJ, James EA, Mai DT, Greenbaum CJ, Kwok WW -
Sep 2014
Recognition of posttranslationally modified GAD65 epitopes in subjects with type 1 diabetes.
DiabetesMcGinty JW, Chow IT, Greenbaum CJ, Odegard JM, Kwok WW, James EA -
Aug 2014
Hyaluronan and hyaluronan-binding proteins accumulate in both human type 1 diabetic islets and lymphoid tissues and associate with inflammatory cells in insulitis.
DiabetesBogdani M, Johnson PY, Potter-Perigo S, Nagy N, Day AJ, Bollyky PL, Wight TN -
Aug 2014
Disease progression among 446 children with newly diagnosed type 1 diabetes located in Scandinavia, Europe, and North America during the last 27 yr.
Pediatr DiabetesMax Andersen ML, Nielsen LB, Svensson J, Pörksen S, Hougaard P, Beam C, Greenbaum CJ, Becker D, Petersen JS, Hansen L, Mortensen HB -
May 2014
Urinary excretion of RAS, BMP, and WNT pathway components in diabetic kidney disease.
Physiol RepAfkarian M, Hirsch IB, Tuttle KR, Greenbaum CJ, Himmelfarb J, de Boer IH -
May 2014
Low HERV-K(C4) copy number is associated with type 1 diabetes.
DiabetesMason MJ, Speake C, Gersuk VH, Nguyen QA, O'Brien KK, Odegard JM, Buckner JH, Greenbaum CJ, Chaussabel D, Nepom GT -
Apr 2014
Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment.
Diabetes CareOrban T, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Marks JB, Monzavi R, Moran A, Peakman M, Raskin P, Russell WE, Schatz D, Wherrett DK, Wilson DM, Krischer JP, Skyler JS, Type 1 Diabetes TrialNet Abatacept Study Group. -
Dec 2013
Anti-cytokine therapies in T1D: Concepts and strategies.
Clin ImmunolNepom GT, Ehlers M, Mandrup-Poulsen T -
Nov 2013
Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders.
DiabetesHerold KC, Gitelman SE, Ehlers MR, Gottlieb PA, Greenbaum CJ, Hagopian W, Boyle KD, Keyes-Elstein L, Aggarwal S, Phippard D, Sayre PH, McNamara J, Bluestone JA, AbATE Study Team. -
Aug 2013
Use of a "fuzzy logic" controller in a closed-loop artificial pancreas.
Diabetes Technol TherMauseth R, Hirsch IB, Bollyky J, Kircher R, Matheson D, Sanda S, Greenbaum CJ -
Jun 2013
Response to Comment on: Greenbaum et al. Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite type 1 diabetes TrialNet data. Diabetes 2012;61:2066-2073.
DiabetesGreenbaum CJ, Beam CA, Type 1 Diabetes TrialNet Study Group. -
May 2013
Immunological biomarkers: catalysts for translational advances in autoimmune diabetes.
Clin Exp ImmunolAhmed ST, Akirav E, Bradshaw E, Buckner JH, McKinney E, Quintana FJ, Waldron-Lynch F, Nepom GT
